AstraZeneca just dropped some jaw-dropping lung cancer trial results: their Tagrisso + chemo combo is helping patients live nearly four years—almost a year longer than Tagrisso alone! The combo slashed the risk of death by 23%, and nearly half the patients made it to four years. Side effects? Manageable, mostly from chemo. Tagrisso’s already a global superstar, and this just cements its place as a game-changer for EGFR-mutated lung cancer. Plus, AstraZeneca’s sales and stock are soaring. Huge win for patients and investors! #Health #BodyHealth #AstraZeneca